{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"11.6","value":"6.6"},{"groupId":"OG001","lowerLimit":"4.6","upperLimit":"10.4","value":"7.5"},{"comment":"The median is the actual observed value for this participant. The confidence interval was not assessable due to insufficient number of participants with events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"16.6"},{"comment":"The upper confidence interval was not assessable due to insufficient number of participants with events.","groupId":"OG003","lowerLimit":"10.1","upperLimit":"NA","value":"18.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"description":"A secondary efficacy endpoint is DOR as assessed by the investigator. The DOR is defined as the time from the date that a confirmed response per modified RECIST Version 1.1/PCWG3 is first reported to the time that progressive disease (PD) is first documented. Progressive disease is defined using RECIST v1.1, as at least a 20% increase in the sum of the diameters of target lesions, or an unequivocal increase in non-target lesions, or the appearance of new lesions. PCWG3 criteria is used to document evidence of disease progression in bone lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a deleterious BRCA (breast cancer susceptibility gene) mutation detected in their tumor.","id":"OG000","title":"BRCA Mutation"},{"description":"Patients with a deleterious ATM (ataxia telangiectasia mutated serine/threonine kinase) mutation detected in their tumor.","id":"OG001","title":"ATM Mutation"},{"description":"Patients with a deleterious CHEK2 (Checkpoint Kinase 2) mutation detected in their tumor.","id":"OG002","title":"CHEK2 Mutation"},{"description":"Patients with other deleterious HRR (homologous recombination repair) gene mutation detected in their tumor.","id":"OG003","title":"Other Gene Mutation"}],"paramType":"MEDIAN","populationDescription":"Patients with a confirmed response in the Investigator Efficacy Population. The Investigator efficacy population is defined by measurable disease status at baseline using modified RECIST Version 1.1 criteria per the investigator. Note, there were no patients with confirmed response by investigator in the CDK12 arm.","reportingStatus":"POSTED","timeFrame":"Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.","title":"Duration of Response (DOR) by Gene in Patients With Confirmed Response Per Investigator","type":"SECONDARY","unitOfMeasure":"months"}